<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>18</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2019</Year>
        <Month>06</Month>
        <Day>08</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Isolation of a Novel Anti-KDR3 Single-chain Variable Fragment Antibody from a Phage Display Library</title>
    <FirstPage>289</FirstPage>
    <LastPage>299</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Shirafkan</FirstName>
        <LastName>Kordi</LastName>
        <affiliation locale="en_US">Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran AND Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Rahmati-Yamchi</LastName>
        <affiliation locale="en_US">Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mehdi</FirstName>
        <LastName>Asghari Vostakolaei</LastName>
        <affiliation locale="en_US">Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Etemadie</LastName>
        <affiliation locale="en_US">Department of Medical Biotechnology, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Abolfazl</FirstName>
        <LastName>Barzegari</LastName>
        <affiliation locale="en_US">Research Centre for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Jalal</FirstName>
        <LastName>Abdolalizadeh</LastName>
        <affiliation locale="en_US">Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran AND Faculty of Paramedicine, Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2018</Year>
        <Month>08</Month>
        <Day>29</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Vascular endothelial growth factor receptor 2 (VEGFR-2) is known as one of the important antigens playing a vital role in angiogenesis. In this study, phage display technology (PDT) was used to produce a single-chain variable fragment (scFv) antibody against a region of the domain 3 in VEGFR-2 called kinase insert domain receptor 3 (KDR3). After designing the KDR3 peptide and biopanning, a colony was chosen for scFv antibody expression. Following expression and purification; western blotting, dot blotting and immunofluorescence (IF) were used to evaluate the antibody function. Surface plasmon resonance (SPR) was also employed to measure affinity of produced antibody. Once a colony was selected and transferred to the expression host, the scFv antibody was expressed in the expected range of 28 kDa. Using a designed chromatography column, antibody purification was found to be about 95%. In this study, a novel scFv with the capability of binding to KDR3 was isolated and purified and its intracellular function was investigated and verified.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2121</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/2121/1422</pdf_url>
  </Article>
</Articles>
